Ventripoint Signs on AngioConsult/Angiopro as European Distributor
 | |||||||||
 |  |  |  |  | |||||
Toronto, Ontario – TheNewswire – April 7, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce it has signed Angiopro GmbH as Ventripoint’s European Distributor for Ventripoint’s products and engaged AngioConsult, their affiliated company to tailor the marketing efforts to the different countries in the EU.
Dr. George Adams, CEO, said “AngioConsult and Angiopro are strong and well-established companies that are recognized for its track record for introducing similar products on the European market, so it is exciting to have such an experienced partner.”
Mr. Benjamin J. Rieck, CEO of both companies, said: “At AngioConsult and Angiopro, we have been pursuing the goal of bringing innovations to the European market and continuously improving patient care since the company was founded. We are very proud to collaborate with Ventripoint as its very promising technology which aligns with our strategy of providing physicians with patient screening and diagnostic solutions.”
AngioConsult and Angiopro are both based in Germany. While AngioConsult is a consulting firm that specializes in market access, product management, sales organization as well as training programs in one company, Angiopro is a classic distributor company focusing on the distribution of medical devices and software products in the cardiology, vascular surgery, and radiology/angiology fields. AngioConsult will combine its consulting arm with its distribution partner, Angiopro, to position Ventripoint in the European market. AngioConsult was selected based on its reputation in the cardiovascular market, alignment with Ventripoint’s current customer base, and an extensive distribution network with contacts to professional decision makers in the cardiovascular field.
About AngioConsult GmbH:
Since more than 12 years AngioConsult, a German based healthcare consulting company, pursues the overarching goal of bringing healthcare innovation to the patient. The AngioConsult team is specialized in consulting services for the clinical sector and combines expertise in research, management, sales, marketing, training/ preclinical and field operations. They provide all skills needed to drive projects through the entire product lifecycle and to support in overcoming all hurdles on the way. For further information please visit angioconsult.de and feel free to contact.
About Angiopro GmbH:
Angiopro is a German family-run company and is a reliable partner for the distribution of medical devices since more than 30 years. The Angiopro team consists of specialists in innovative products and technologies in cardiovascular medicine and stands for exclusive sales, intensive advice, and comprehensive services in the field of vascular medicine. Due to their special medical knowledge, their extensive distribution network with contacts to professional decision makers in the cardiovascular field, Angiopro is a strong and efficient sales partner for medical device and healthcare IT solution companies. If you want to learn more about Angiopro’s competencies, please visit angiopro.de and feel free to contact.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
About VMS+ Technology
VMS+ (Ventripoint Medical System Plus) 3.0 marries the high-resolution of cardiac MRI (Magnetic Resonance Imaging) and ease of use of ultrasound with the power of Ventripoint’s proprietary KBR (Knowledge-Based Reconstruction) AI technology. KBR enables physicians to construct a precise 3D model of the heart and calculate volumes and ejection fractions for all chambers of the heart with an accuracy equivalent to MRI using standard ultrasound images obtained using any cardiac ultrasound machine such as General Electric, Phillips, Siemens, etc.
For further information, please contact:
Mr. John Grosso
Mr. Cory Bataan
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.